A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Investigator Perspectives
A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
Saeed Sadeghi, MD, comments on the utilization of FGFR2 inhibitors as treatment for advanced cholangiocarcinoma.
A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).
A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.
How the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.
Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Follicular Lymphoma
Lung Cancer
Colorectal Cancer
Chronic Lymphocytic Leukemia
Multiple Myeloma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Graft versus Host Disease
Ovarian Cancer
Non-Hodgkin Lymphoma
Prostate Cancer
Graft versus Host Disease
Graft versus Host Disease
Graft versus Host Disease
Follicular Lymphoma
Multiple Myeloma
Bladder Cancer
